Screener
AbCellera Biologics Inc. ABCL Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | December 31, 2025 | June 30, 2026 |
|---|---|---|
| Deferred revenue | 13,526 | 20,705 |
| Total current liabilities | 64,307 | 53,189 |
| Long-term liabilities: | ||
| Operating lease liability | 137,403 | 129,948 |
| Deferred revenue | 3,500 | 40,450 |
| Deferred government contributions | 174,453 | 178,254 |
| Other long-term liabilities | 10,383 | 9,714 |
| Total long-term liabilities | 325,739 | 358,366 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s operating lease liabilities?
- AbCellera Biologics Inc. (ABCL) reported operating lease liabilities of $129.95M in Q2 2026.
- How has AbCellera Biologics Inc.'s operating lease liabilities changed year-over-year?
- AbCellera Biologics Inc.'s operating lease liabilities decreased by 5.3% year-over-year, from $137.18M to $129.95M.
- What is the long-term trend for AbCellera Biologics Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s operating lease liabilities has grown at a 105.9% compound annual growth rate (CAGR), from $3.72M to $137.4M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about AbCellera Biologics Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude